Target intelligence / Profile preview

Virus particle surface protein (VSP)

Target
VSP
Molecular classification
Virus envelope glycoprotein, Virus capsid protein, Viral fusion protein, Other (virus-like particle surface proteins)
01

Overview

Virus particle surface proteins are the structural and functional molecules that form the outer layer of virus particles, either as capsid proteins in non-enveloped viruses or envelope glycoproteins in enveloped viruses. They are essential for virus transmission and cell entry, mediating host recognition, receptor binding, and membrane fusion. Because they are exposed and immunogenic, these proteins are the principal targets for vaccines, neutralizing antibodies, and entry/fusion inhibitors. The specific protein and its function vary depending on the virus, with examples such as the spike protein of coronaviruses, hemagglutinin of influenza viruses, and E protein of flaviviruses playing crucial roles in viral infectivity and immune recognition. Note: The target as named, "Virus Particle Surface", is too generic and not standard—specificity (protein name, virus species) is needed for accurate downstream annotation.

Other names
Virus surfaceViral envelope proteinViral capsid proteinSurface antigenVirus spike proteinHemagglutininSpike proteinE glycoprotein
02

Mechanism of action

Inhibition of receptor binding (blocking protein-receptor interface); Inhibition of membrane fusion (blocking conformational changes necessary for fusion); Immune neutralization (antibody-mediated blockade of viral entry)

03

Biological functions

Receptor binding and host cell attachmentMembrane fusion (for enveloped viruses)Immune evasion (via antigenic variation and glycan shielding)Virus assembly and budding
04

Disease associations

Infection (facilitate infection and spread of viral diseases such as SARS, influenza, HIV, dengue, Zika, etc.)Target for vaccine development and antiviral therapy
05

Safety considerations

Antigenic variability (mutation and diversity limit long-term efficacy)Antibody-dependent enhancement (rare cases in some viral families)Autoimmune cross-reactivity (rare)Potential for allergenicity with vaccine candidates
06

Interacting drugs

Neutralizing antibodies

3 more in the full profile.

07

Biomarkers

Surface antigens detectable in patient sera (e.g., HBsAg for hepatitis B, spike protein for SARS-CoV-2)Anti-surface protein antibodies (e.g., anti-spike IgG)

Beyond the preview

Go deeper on Virus particle surface protein (VSP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virus particle surface protein (VSP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call